StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

Lexeo Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Lexeo Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $66.64M, down 9.6% year over year. For fiscal 2025 it was $63.80M, down 13.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$63.80M-13.9%
FY2024Dec 31, 2024$74.09M+39.5%
FY2023Dec 31, 2023$53.13M+8.1%
FY2022Dec 31, 2022$49.16M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.03M+29.3%
Q1 FY2026Mar 31, 2026$15.70M-8.5%
Q4 FY2025Dec 31, 2025$16.21M-11.7%
Q3 FY2025Sep 30, 2025$15.70M-33.0%
Q2 FY2025Jun 30, 2025$14.72M-11.1%
Q1 FY2025Mar 31, 2025$17.17M+9.1%
Q4 FY2024Dec 31, 2024$18.37M+123.7%
Q3 FY2024Sep 30, 2024$23.42M+35.8%
Q2 FY2024Jun 30, 2024$16.56M+47.4%
Q1 FY2024Mar 31, 2024$15.74M-4.2%
Q4 FY2023Dec 31, 2023$8.21M-27.9%
Q3 FY2023Sep 30, 2023$17.25M+12.3%
Q2 FY2023Jun 30, 2023$11.24M–
Q1 FY2023Mar 31, 2023$16.44M–
Q4 FY2022Dec 31, 2022$11.39M–
Q3 FY2022Sep 30, 2022$15.36M–

More Lexeo Therapeutics figures

See a number that looks wrong?